Homepage > Company > Media > Pharma News > 2021 > FDA Accepts Investigational New Drug Application and Grants Fast Track Designation of Trehalose for Spinocerebellar Ataxia Treatment

FDA Accepts Investigational New Drug Application and Grants Fast Track Designation of Trehalose for Spinocerebellar Ataxia Treatment

The FDA has granted the program Fast Track designation for SCA, and trehalose has previously received Orphan Drug designation for spinocerebellar ataxia type 3 (SCA3). Trehalose is administered as a 90.5 mg/mL intravenous infusion.

"SCA is a highly debilitating neurodegenerative disease that currently lacks a cure or an approved therapeutic and as such, patients manage symptoms through physical therapy and other symptomatic treatments," said Raj Mehra, PhD, chairman and chief executive officer of Seelos. "SLS-005 has already displayed encouraging open label human data in SCA3, the most common type of SCA, and our team has taken that experience and knowledge into the design and plans for our global phase 2b/3 placebo-controlled study. We look forward to initiating this study in early 2022 and our recent capital raises have accounted for the expected development costs for initiating this study."

Trehalose had been studied in a 6-month open-label phase 2a study that also included an additional 6-month follow up in participants with SCA3, also known as Machado-Joseph Disease. In an open-label study, 14 participants with SCA3 treated for 6 months with trehalose had stable Scale for Assessment and Rating of Ataxia (SARA) scores. Out of the 14 participants, 6 received treatment for as long as 12 months and continued to have stable SARA scores. Natural history data for SCA3 suggests a measurable increase on SARA would have been seen within 12 months without treatment.

"On behalf of the National Ataxia Foundation and the ataxia community we represent, we're thrilled that Seelos Therapeutics has received both IND acceptance and Fast Track designation from the FDA," said Andrew Rosen, NAF executive director. "Seelos is a founding member of the NAF Drug Development Collaborative and NAF looks forward to working closely with Seelos to support the company as its program progresses."

November 15, 2021

https://practicalneurology.com/

Read also

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Pfizer’s antibiotic combination, Emblaveo (aztreonam-avibactam), has been approved by the European Commission (EC) to treat patients with multidrug-resistant infections.

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC

The FDA has approved nogapendekin alfa inbakicept-pmln (Anktiva; N-803) in combination with Bacillus Calmette–Guérin (BCG) for the treatment of adult patients with BCG-unresponsive ...

Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label ...

Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies

Ipsen and Skyhawk Therapeutics have announced an exclusive worldwide collaboration aimed at advancing RNA-targeting therapies for rare neurological diseases, with the deal worth more than $1.8bn.